Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Accelerating the pulse of cardiovascular R&D

Nature Reviews Drug Discovery volume 9, pages 823–824 (2010)Cite this article

Subjects

Abstract

Renewed commitment to cardiovascular drug development is needed to combat what is likely to be the leading cause of death for the next two decades. How might this be achieved?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Garber, A. M. An uncertain future for cardiovascular drug development? N. Engl. J. Med. 360, 12 (2009).

    Article  Google Scholar 

  2. World Health Organization. Cardiovascular diseases (CVDs), [online] (2009)

  3. Yang, W. et al. Prevalence of diabetes among men and women in China. N. Engl. J. Med. 362, 1090–1101 (2010).

    Article  CAS  Google Scholar 

  4. FDA approves updated warfarin (Coumadin) prescribing information. [online], (2007).

  5. Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).

    Article  CAS  Google Scholar 

  6. Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403–1419 (2008).

    Article  CAS  Google Scholar 

  7. Amar, L. et al. Aldosterone synthase inhibition with LCI699. A proof-of-concept study in patients with primary aldosteronism. Hypertension 13 Sep 2010 (doi: 10.1161/HYPERTENSIONAHA.110.157271).

  8. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Andrew Plump, M.D., Ph.D., is Vice President and Cardiovascular Disease Franchise Worldwide Discovery Head, Merck Research Laboratory, 126 East Lincoln Avenue Rahway, New Jersey 07065, USA. andrew_plump@merck.com,

    Andrew Plump

Authors
  1. Andrew Plump
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

A.P. is employed by Merck and Co., Inc. Whitehouse Station, New Jersey, USA.

Supplementary information

Supplementary information Figure S1

50 years of advances in cardiovascular disease therapies. (PDF 260 kb)

Supplementary information Figure S2

Alliances by therapeutic category. (PDF 191 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plump, A. Accelerating the pulse of cardiovascular R&D. Nat Rev Drug Discov 9, 823–824 (2010). https://doi.org/10.1038/nrd3315

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3315

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research